A Catalog of 5’ Fusion Partners in ROS1-Positive NSCLC Circa 2020

by Sai-Hong Ignatius Ou, MD PhD, Misako Nagasaka, MD
Published 2020-09-01

Catalog of 5′ fusion partners in RET+ NSCLC Circa 2020

by Sai-Hong Ignatius Ou, MD, PhD, Viola W. Zhu, MD, PhD
Published 2020-06-01

Catalog of 5’ Fusion Partners in ALK-positive NSCLC Circa 2020

by Sai-Hong Ignatius Ou, MD, PhD, Viola W. Zhu, MD, PhD, Misako Nagasaka, MD
Published 2020-03-01

A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review

by Viola W. Zhu, MD, PhD, Misako Nagasaka, MD, Russell Madison, BA, Alexa B. Schrock, PhD, Jean Cui, PhD, Sai-Hong Ignatius Ou, MD, PhD
Published 2021-01-01

Efficacy of Taletrectinib (AB-106/DS-6051b) in ROS1+ NSCLC: An Updated Pooled Analysis of U.S. and Japan Phase 1 Studies

by Sai-Hong Ignatius Ou, MD, PhD, Yutaka Fujiwara, MD, PhD, Alice T. Shaw, MD, PhD, Noboru Yamamoto, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Frank Fan, MD, Yuki Hao, MSc, Yanfei Gao, MSc, Pasi A. Jänne, MD, Takashi Seto, MD
Published 2021-01-01

Identification of Novel CDH1-NRG2α and F11R-NRG2α Fusions in NSCLC Plus Additional Novel NRG2α Fusions in Other Solid Tumors by Whole Transcriptome Sequencing

by Sai-Hong Ignatius Ou, MD, PhD, Joanne Xiu, PhD, Misako Nagasaka, MD, Bing Xia, MD, Shannon S. Zhang, MD, Qing Zhang, PhD, Jeffrey J. Swensen, PhD, David Spetzler, MS, PhD, MBA, Wolfgang Michael Korn, MD, Viola W. Zhu, MD, PhD, Stephen V. Liu, MD
Published 2021-02-01